Pneumagen Raises £3.8 Million To Advance The Phase Ii Clinical Development Of Neumifil, A Pan-Antiviral, Intranasal Drug For The Prophylaxis And Treatment Of Viral Respiratory Tract Infections (Rtis)
Jan 19, 2022•over 3 years ago
Amount Raised
£3.8 Million
Round Type
seed
Description
Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced it has raised a further £3.8m to advance clinical development and manufacturing of its lead product Neumifil.
FundzWatch™ Score
65
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood